These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38722382)

  • 1. Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.
    Shalaby N; Xia Y; Kelly JJ; Sanchez-Pupo R; Martinez F; Fox MS; Thiessen JD; Hicks JW; Scholl TJ; Ronald JA
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3176-3190. PubMed ID: 38722382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
    Li Y; Hermanson DL; Moriarity BS; Kaufman DS
    Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of [
    Niu M; Qin J; Wang L; He Y; Tian C; Chen Y; Huang P; Peng Z
    Mol Imaging; 2022; 2022():2679260. PubMed ID: 35330799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
    Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
    Front Immunol; 2020; 11():581468. PubMed ID: 33193388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.
    Cortese M; Torchiaro E; D'Andrea A; Petti C; Invrea F; Franco L; Donini C; Leuci V; Leto SM; Vurchio V; Cottino F; Isella C; Arena S; Vigna E; Bertotti A; Trusolino L; Sangiolo D; Medico E
    Mol Ther; 2024 Aug; 32(8):2741-2761. PubMed ID: 38894542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer.
    Ao X; Yang Y; Li W; Tan Y; Guo W; Ao L; He X; Wu X; Xia J; Xu X; Guo J
    J Immunother; 2019 Oct; 42(8):284-296. PubMed ID: 31261167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress.
    Budi HS; Ahmad FN; Achmad H; Ansari MJ; Mikhailova MV; Suksatan W; Chupradit S; Shomali N; Marofi F
    Stem Cell Res Ther; 2022 Jan; 13(1):40. PubMed ID: 35093187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
    Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Jiang H; DeGrado TR
    Theranostics; 2018; 8(14):3918-3931. PubMed ID: 30083270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
    Sakemura R; Bansal A; Siegler EL; Hefazi M; Yang N; Khadka RH; Newsom AN; Hansen MJ; Cox MJ; Manriquez Roman C; Schick KJ; Can I; Tapper EE; Nevala WK; Adada MM; Bezerra ED; Kankeu Fonkoua LA; Horvei P; Ruff MW; Parikh SA; Pandey MK; DeGrado TR; Suksanpaisan L; Kay NE; Peng KW; Russell SJ; Kenderian SS
    Cancer Immunol Res; 2021 Sep; 9(9):1035-1046. PubMed ID: 34244299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
    Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
    Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
    Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
    Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
    J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo PET Imaging of
    Pham TT; Chenoweth A; Patel N; Banu A; Osborn G; Blower PJ; Karagiannis SN; Ma MT
    J Nucl Med; 2024 Jul; 65(7):1035-1042. PubMed ID: 38844362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect
    Silvestre RN; Eitler J; de Azevedo JTC; Tirapelle MC; Fantacini DMC; de Souza LEB; Swiech K; Covas DT; Calado RT; Montero PO; Malmegrim KCR; Figueiredo ML; Tonn T; Picanço-Castro V
    Front Immunol; 2023; 14():1226518. PubMed ID: 37818365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.